Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
Currently, there are no established 2nd-line or salvage chemotherapy regimens for patients
with HRPC, many of whom retain an excellent performance status. The antitumor characteristics
and toxicity profile of vinflunine make it an ideal agent to be investigated in this setting.
In this Phase II trial, we plan to evaluate the efficacy, toxicity, and feasibility of
administering IV vinflunine at a dose of 320 mg/m2 q3w as salvage chemotherapy in patients
with HRPC. The patients will be evaluated for response, survival, and toxicity. If
significant antitumor activity is demonstrated, further evaluation of this agent either alone
or combination regimens and at earlier stages of disease will be indicated.